Dr. Daniel Hicklin has served as a member of our Board of Directors since the Company’s formation in late 2016 and is an accomplished cancer researcher and biopharmaceutical executive with over three decades of oncology drug development experience. Currently, Dr. Hicklin holds a number of executive positions including Executive Partner at MPM Capital, Founder and CEO of Werewolf Therapeutics, President of Trieza Therapeutics and Board member of Tizona Therapeutics. Prior to his current positions, he co-founded Potenza Therapeutics (acquired by Astellas Pharma) where he was President and CEO, and served as President and CSO of CoStim Pharmaceuticals (acquired by Novartis).
Earlier in his career, he held several positions at Merck Research Laboratories and the former Schering-Plough Research Institute, most recently leading Biologics Strategy for Oncology and overseeing immuno-oncology discovery research at Merck Research Laboratories in Boston. Dr. Hicklin began his drug development career at ImClone Systems where he held several positions of increasing responsibility, including Vice President of Experimental Therapeutics. Dr. Hicklin’s team at ImClone supported the development and FDA approval of the cancer treatment Erbitux® (cetuximab) and built a diversified portfolio of antibody therapeutics including Cyramza® (ramucirumab), Portrazza® (necitumumab), Lartruvo® (olaratumab) and other cancer therapies that were acquired by Eli Lilly in 2008.
Dr. Hicklin has co-authored over 200 peer-reviewed publications and is an inventor on numerous issued and pending patents. Dr. Hicklin received his Master’s and Ph.D. in Microbiology & Immunology from New York Medical College and earned his B.S. from the University of Iowa.